How Ph.D. was paid
$8.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Eric Dube, Ph.D.President, Chief Executive Officer and Director | $854,250 | $3,314,520 | $3,309,384 | $964,125 | $14,872 | $8,457,151 |
| Christopher ClineChief Financial Officer | $522,917 | $583,110 | $738,247 | $393,750 | $12,890 | $2,250,914 |
| Peter HeermaChief Commercial Officer | $527,917 | $583,110 | $738,247 | $397,500 | $14,977 | $2,261,751 |
| Jula Inrig, M.D.Chief Medical Officer | $568,084 | $757,020 | $1,272,840 | $429,000 | $14,688 | $3,041,632 |
| William E. Rote, Ph.D.Chief Research Officer | $522,334 | $583,110 | $738,247 | $393,000 | $19,774 | $2,256,465 |
What changed and why
- $8.5MCEO Eric Dube received total compensation of $8,457,151 in 2025 compared to $5,204,877 in 2024.
- $410.5MNet product sales reached approximately $410.5 million, representing a more than 80% year-over-year increase.
- 150%The Compensation Committee determined that corporate objectives were achieved at the 150% level.
- 96%The 2025 say-on-pay proposal was approved with approximately 96% support.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.